OAM
RYTM icon

Oxford Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Oxford Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,538
Closed -$559K – 716
2025
Q3 		$559K Buy
+5,538
New +$514K 0.19% 171
2018
Q4 		– Sell
-11,426
Closed -$332K – 2059
2018
Q3 		$332K Sell
11,426
-2,750
-19% -$86.9K 0.01% 1471
2018
Q2 		$445K Buy
+14,176
New +$388K 0.01% 1380

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oxford Asset Management's RYTM Position: Q4 2025 in Review

Oxford Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 5,538 shares — an estimated $559K sold.

Oxford Asset Management first reported a position in RYTM in Q2 2018 and held it in 3 quarters. The position peaked at $559K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Oxford Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 5,538 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $559K.
  • Oxford Asset Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Oxford Asset Management's Rhythm Pharmaceuticals position peaked at $559K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.